• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Risk of major adverse cardiovascular events varies with dynamic metabolic syndrome status

byThomas SuandDeepti Shroff Karhade
December 4, 2019
in Cardiology, Chronic Disease, Endocrinology, Gastroenterology, Public Health
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In this retrospective study involving South Koreans with no history of major adverse cardiovascular events (MACE), persons who developed metabolic syndrome (MetS) within the three-year inclusion period were at significantly increased risk of MACE versus those who remained free of the condition. Persons who had MetS at the beginning of the study and recovered before the end faced a significantly lower MACE risk compared to those who did not.

2. While MetS-developed and MetS chronic patients had similar risks for MACE, patients in the MetS-recovery group retained a higher risk than patients in the MetS-free group, underscoring the immediacy and persistence of the condition’s effects on the cardiovascular system.

Evidence Rating Level: 2 (Good)

Study Rundown: While it is well known that patients with metabolic syndrome (MetS) face an increased risk for major adverse cardiovascular events (MACE), it is unclear whether development of or recovery from MetS affects the incidence rate of MACE. Given the increasing medical burden of these concomitant illnesses, it is essential to better characterize this association. This study relied on health screening data from the National Health Insurance Service of Korea and found that MACE risk varied strongly with dynamic MetS status during the three-year inclusion period. The MetS-chronic group faced the highest risk, followed by the MetS-developed, MetS-recovery, and MetS-free groups, respectively. The components of MetS were analyzed, and hypertension was found to have the strongest association with MACE risk. These results support preventative public health policies and highlight the clinical importance of a MetS history. A major strength of this study was that it utilized comprehensive health information from an extremely large population. However, this study’s retrospective nature made it difficult to detecting confounding factors, and the short follow-up and homogenous cohort composition affected generalizability of findings.

Click here to read the study in Annals of Internal Medicine

Relevant Reading: The Global Epidemic of the Metabolic Syndrome

In-Depth [retrospective cohort]: In this nationwide population-based study, South Korean adults with no history of MACE were divided into four categories according to MetS status over a 3-year timeframe. Over 9.5 million persons met the inclusion criteria of identifiable MetS status at 3 or more health examinations during the inclusion period. Some exclusion criteria were transient change in MetS status, change in MetS status at the third examination, and underlying kidney function impairment. Persons were considered to have MetS if they displayed 3 or more of the following components: increased waist circumference (≥90 cm for Asian men and ≥80 cm for Asian women); elevated triglyceride level (≥50 mg/dL); reduced high-density lipoprotein cholesterol level (<40 mg/dL for men and 50 mg/dL for women); elevated blood pressure (systolic ≥130 mm Hg and/or diastolic ≥80 mm Hg); and elevated fasting glucose level (≥100 mg/dL). Of these components, development of and recovery from hypertension had the greatest impacts on MACE risk. MACE occurred most frequently in the MetS-chronic group (8.52 events per 1000 person-years) and MetS-developed group (6.05 events per 1000 person-years). The MetS-recovery group (4.55 events per 1000 person-years) and MetS-free group (1.92 events per 1000 person-years) faced the lowest risk of MACE.

RELATED REPORTS

Subsidization of supermarkets may help reduce obesity risk in children

Wellness Check: Nutrition

Unsweetened coffee consumption is associated with reduced risk of mortality

Image: PD

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: cardiac riskhypertensionmetabolic syndromemortalityobesity
Previous Post

#VisualAbstract: Clinical presentation, treatment, and short-term outcomes of lung injury associated with e-cigarettes or vaping

Next Post

#VisualAbstract: Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

RelatedReports

Meeting families, demographic information affect child abuse work-up
Pediatrics

Subsidization of supermarkets may help reduce obesity risk in children

June 27, 2022
Provision of medically-tailored meals linked with lower admissions and medical spending
Wellness

Wellness Check: Nutrition

June 23, 2022
European data showed coffee consumption associated with lower mortality
Cardiology

Unsweetened coffee consumption is associated with reduced risk of mortality

June 21, 2022
Improved glycemic control in type 1 diabetics on very low-carbohydrate diets
Cardiology

Review suggests mixed evidence for relationship between food insecurity and childhood obesity

June 14, 2022
Next Post
#VisualAbstract: Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

#VisualAbstract: Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Adalimumab aids in control of noninfectious uveitis

Optic nerve ultrasonography can be used to detect elevated intracranial pressure

#VisualAbstract: Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis

#VisualAbstract: Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Sickle cell trait associated with preexisting kidney comorbidities and increased COVID-19 mortality
  • Adding atezolizumab to standard of care treatment for human epidermal growth factor receptor 2 (HER2) positive early breast cancer does not improve pathologic response outcomes
  • FOLFOX combined with nivolumab and trastuzumab in ERBB2-positive esophagogastric adenocarcinoma is an emerging therapy option
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.